'ALL HAS TO BE BUILT FROM SCRATCH'Manufacturing capacity has been easier to locate for vaccine candidates that employ traditional technology.
But three of the candidates CEPI is backing involve more complex mRNA- or DNA-based technology.Since there has never been a licensed vaccine using those approaches, no network of contract manufacturers exists to support high-volume production, Robinson said."The capacity just isn't there and it all has to be built from scratch," he said.Access to medical glass is another known bottleneck.